Enfortumab Vedotin Impresses In Urothelial Cancer After Chemo, Immunotherapies
Executive Summary
The antibody-drug conjugate being evaluated by Astellas and Seattle Genetics has posted “remarkable” positive top-line results in locally advanced or metastatic urothelial cancer, with a US BLA submission expected later in 2019.
You may also be interested in...
What Late-Breakers To Look Out For At ASCO 2019
Delegates at this year’s ASCO meeting in Chicago will hear late-breaking clinical data for a number of studies from AstraZeneca, Novartis, Pfizer, Astellas, Merck & Co and Seattle Genetics which are set to shake up their respective markets. There will also be more clarity on where Lilly’s Lartruvo went so wrong.
Innovation The Centerpiece In Mixed Japan 2019 Outlook
2019 has already brought one industry-shaking event in Japan with the formal completion of the Takeda-Shire deal. But how will this play out and what else can we expect in this key market over the next year?
Astellas Exercises Option To Acquire Potenza, For Up To $405m
Astellas has exercised an option to acquire Potenza, paying up to $404.7m in cash for the private US venture in a deal that will boost its presence in immuno-oncology.